Literature DB >> 6508983

Stereoselective ring oxidation of propranolol in man.

T Walle, U K Walle, M J Wilson, T C Fagan, T E Gaffney.   

Abstract

The objective of this study was to elucidate stereoselective mechanisms of propranolol metabolism in man. Five normal subjects were given single 80 mg oral doses of deuterium-labeled pseudoracemates of propranolol, and the stereochemical composition of propranolol and its major metabolites in urine was determined by GC/MS. The (-)/(+)-enantiomer ratios for unchanged propranolol, 1.50 +/- 0.10 (mean +/- s.e. mean), and propranolol glucuronide, 1.76 +/- 0.10, were similar to previous findings in plasma. All products of side-chain oxidation also consisted mainly of the (-)-enantiomer, with an overall (-)/(+) ratio of 1.61 +/- 0.11. A (-)/(+) ratio of 1.04 +/- 0.17 for 4-hydroxypropranolol did not indicate stereoselectivity in ring oxidation. However, the ratio for its glucuronic acid conjugate of 1.78 +/- 0.19 and for its sulphate conjugate of 0.27 +/- 0.03 suggested stereoselectivity in either the glucuronidation or sulphation of 4-hydroxypropranolol, or both. When the stereoselectivity in these secondary pathways was taken into consideration, the overall ring oxidation strongly favoured (+)-propranolol with a (-)/(+)-enantiomer ratio of 0.59 +/- 0.09. The composite observations of the stereochemistry of propranolol metabolism in man are consistent with stereoselective ring oxidation of (+)-propranolol, leading to a greater bioavailability of the pharmacologically more active (-)-propranolol and subsequent preferential side-chain oxidation and glucuronidation of this enantiomer.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6508983      PMCID: PMC1463559          DOI: 10.1111/j.1365-2125.1984.tb02537.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  23 in total

1.  Disposition of propranolol. V. Drug accumulation and steady-state concentrations during chronic oral administration in man.

Authors:  G H Evans; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

2.  The disposition of propranolol. I. Elimination during oral absorption in man.

Authors:  D G Shand; R E Rangno
Journal:  Pharmacology       Date:  1972       Impact factor: 2.547

3.  The predictable relationship between plasma levels and dose during chronic propranolol therapy.

Authors:  T Walle; E C Conradi; U K Walle; T C Fagan; T E Gaffney
Journal:  Clin Pharmacol Ther       Date:  1978-12       Impact factor: 6.875

4.  Presystemic and systemic glucuronidation of propranolol.

Authors:  T Walle; T C Fagan; E C Conradi; U K Walle; T E Gaffney
Journal:  Clin Pharmacol Ther       Date:  1979-08       Impact factor: 6.875

5.  Plasma propranolol levels in the quaniitative assessment of beta-adrenergic blockade in man.

Authors:  D J Coltart; D G Shand
Journal:  Br Med J       Date:  1970-09-26

6.  Direct measurement of propranolol bioavailability during accumulation to steady-state.

Authors:  A J Wood; K Carr; R E Vestal; S Belcher; G R Wilkinson; D G Shand
Journal:  Br J Clin Pharmacol       Date:  1978-10       Impact factor: 4.335

7.  Pharmacology of 4-hydroxypropranolol, a metabolite of propranolol.

Authors:  J D Fitzgerald; S R O'Donnell
Journal:  Br J Pharmacol       Date:  1971-09       Impact factor: 8.739

8.  4-Hydroxypropranolol and its glucuronide after single and long-term doses of propranolol.

Authors:  T Walle; E C Conradi; U K Walle; T C Fagan; T E Gaffney
Journal:  Clin Pharmacol Ther       Date:  1980-01       Impact factor: 6.875

9.  Isopropylamine, a biologically active deamination product of propranolol in dogs: identification of deuterated and unlabeled isopropylamine by gas chromatography-mass spectrometry.

Authors:  T Walle; T Ishizaki; T E Gaffney
Journal:  J Pharmacol Exp Ther       Date:  1972-12       Impact factor: 4.030

10.  Stereoselective oral bioavailability of (+/-)-propranolol in the dog. A GC-MS study using a stable isotope technique.

Authors:  T Walle; U K Walle
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1979-03
View more
  9 in total

1.  Monitoring the effects of chiral pharmaceuticals on aquatic microorganisms by metabolic fingerprinting.

Authors:  Emma S Wharfe; Catherine L Winder; Roger M Jarvis; Royston Goodacre
Journal:  Appl Environ Microbiol       Date:  2010-01-29       Impact factor: 4.792

2.  Circadian changes in the pharmacokinetics and cardiovascular effects of oral propranolol in healthy subjects.

Authors:  B Langner; B Lemmer
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  Incorporation of the Time-Varying Postprandial Increase in Splanchnic Blood Flow into a PBPK Model to Predict the Effect of Food on the Pharmacokinetics of Orally Administered High-Extraction Drugs.

Authors:  Rachel H Rose; David B Turner; Sibylle Neuhoff; Masoud Jamei
Journal:  AAPS J       Date:  2017-05-19       Impact factor: 4.009

4.  Polymorphic metabolism of the beta-adrenoreceptor blocking drugs and its clinical relevance.

Authors:  R L Smith
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

5.  Stereochemical characterization of the diastereomers of the phenobarbital N-beta-D-glucose conjugate excreted in human urine.

Authors:  W H Soine; P J Soine; S E Mongrain; T M England
Journal:  Pharm Res       Date:  1990-04       Impact factor: 4.200

6.  Pharmacokinetics of (+)-rolipram and (-)-rolipram in healthy volunteers.

Authors:  W Krause; G Kühne; N Sauerbrey
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

7.  Stereoselective disposition of mexiletine in man.

Authors:  O Grech-Belanger; J Turgeon; M Gilbert
Journal:  Br J Clin Pharmacol       Date:  1986-05       Impact factor: 4.335

8.  Site- and stereospecific ocular drug delivery by sequential enzymatic bioactivation.

Authors:  N Bodor; L Prokai
Journal:  Pharm Res       Date:  1990-07       Impact factor: 4.200

9.  Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound.

Authors:  G Neugebauer; W Akpan; B Kaufmann; K Reiff
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.